CA
NZ
UK
AU
IND
US
…
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -142.07M | -83.95M | -103.26M | -52.53M | -17.35M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | -135.66M | -83.99M | -103.27M | -52.55M | -17.35M |
| Selling general administrative | 89.07M | 59.22M | 22.69M | 11.75M | 0.58M |
| Gross profit | 64.69M | 17.23M | - | - | 0.00M |
| Reconciled depreciation | 3.68M | 0.97M | 0.62M | 0.32M | - |
| Ebit | -131.22M | -173.41M | -104.30M | -55.07M | -4.37M |
| Ebitda | -127.00M | -64.65M | -102.93M | -54.74M | - |
| Depreciation and amortization | 4.22M | 108.76M | 1.37M | 0.32M | - |
| Non operating income net other | 4.22M | -0.22M | 1.37M | - | 0.00M |
| Operating income | -131.22M | -173.41M | -104.30M | -54.74M | -17.41M |
| Other operating expenses | 208.28M | 192.55M | 104.30M | 54.74M | 0.00M |
| Interest expense | 15.98M | 17.59M | 0.34M | 2.54M | 0.00M |
| Tax provision | -6.41M | 0.04M | 0.01M | 0.02M | - |
| Interest income | 3.86M | 0.37M | 1.56M | 2.23M | 0.06M |
| Net interest income | -12.12M | -17.22M | 1.22M | 2.23M | - |
| Extraordinary items | - | - | - | - | 0.00M |
| Non recurring | - | - | - | - | 0.00M |
| Other items | - | - | - | - | 0.00M |
| Income tax expense | -6.41M | 0.04M | 0.01M | 0.02M | 0.00M |
| Total revenue | 77.06M | 19.14M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 195.91M | 190.65M | 104.30M | 54.74M | 4.37M |
| Cost of revenue | 12.37M | 1.90M | - | - | 0.00M |
| Total other income expense net | -10.85M | 89.46M | 1.03M | 2.21M | -21.65M |
| Discontinued operations | - | - | - | - | 0.00M |
| Net income from continuing ops | -135.66M | -83.99M | -103.27M | -52.55M | -26.02M |
| Net income applicable to common shares | -135.66M | -83.99M | -103.27M | -52.55M | -26.02M |
| Preferred stock and other adjustments | - | - | - | - | 0.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 646.62M | 352.91M | 294.65M | 240.86M | 146.71M |
| Intangible assets | 252.93M | 58.95M | 18.74M | - | - |
| Other current assets | 10.94M | 8.95M | 5.27M | 4.53M | 2.70M |
| Total liab | 397.95M | 210.87M | 174.44M | 68.77M | 16.36M |
| Total stockholder equity | 248.67M | -392.82M | 120.21M | -173.17M | -69.90M |
| Deferred long term liab | - | - | 0.20M | - | - |
| Other current liab | 79.65M | 55.11M | 2.00M | 1.26M | 9.33M |
| Common stock | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -556.24M | -392.82M | -257.16M | -173.17M | -69.90M |
| Other liab | - | 144.88M | 129.94M | 47.68M | 0.04M |
| Other assets | 0.00M | 101.38M | 101.79M | 3.22M | 0.32M |
| Cash | 286.33M | 28.00M | 31.34M | 142.09M | 139.95M |
| Total current liabilities | 87.06M | 64.73M | 42.60M | 18.46M | 13.08M |
| Current deferred revenue | -1.10M | - | 30.72M | 13.41M | - |
| Net debt | 21.82M | -25.82M | -28.73M | -138.82M | -136.30M |
| Short term debt | 1.10M | 0.93M | 0.71M | 0.64M | 0.40M |
| Short long term debt total | 308.14M | 2.19M | 2.61M | 3.26M | 3.65M |
| Other stockholder equity | 803.26M | 0.21M | 377.40M | -0.09M | -146.84M |
| Property plant equipment | - | 0.91M | 0.98M | 1.29M | 3.73M |
| Total current assets | 387.54M | 190.22M | 166.59M | 236.35M | 119.36M |
| Long term investments | - | 0.00M | 4.98M | 0.00M | 23.29M |
| Net tangible assets | - | 83.08M | 101.47M | 172.09M | 130.35M |
| Short term investments | 0.00M | 123.72M | 125.20M | 89.73M | 104.69M |
| Net receivables | 67.97M | 23.99M | 3.27M | - | - |
| Long term debt | 306.42M | - | - | - | - |
| Inventory | 22.31M | 5.57M | 1.51M | - | - |
| Accounts payable | 7.42M | 8.69M | 9.17M | 3.15M | 3.35M |
| Accumulated other comprehensive income | 1.64M | -0.22M | -0.04M | 0.08M | 0.13M |
| Common stock total equity | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings total equity | - | -392.82M | -257.16M | -173.17M | - |
| Non currrent assets other | 4.16M | 101.38M | 101.79M | 1.27M | 0.32M |
| Non current assets total | 259.08M | 162.68M | 128.06M | 4.51M | 27.35M |
| Capital lease obligations | 1.72M | 2.19M | 2.61M | 3.26M | 3.65M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 7.98M | -42.43M | 11.34M | -127.78M | -127.50M |
| Change to liabilities | 7.64M | 22.66M | 3.68M | 10.06M | 3.67M |
| Total cashflows from investing activities | 7.70M | 48.55M | 37.87M | -127.78M | -11.25M |
| Net borrowings | - | - | -0.16M | - | 0.07M |
| Total cash from financing activities | 109.09M | 73.47M | 181.29M | 127.18M | 89.75M |
| Change to operating activities | -4.51M | -5.18M | -3.07M | -2.94M | -0.02M |
| Net income | -135.66M | -83.99M | -103.27M | -52.55M | -26.02M |
| Change in cash | -3.34M | -10.75M | 130.12M | -39.99M | 77.94M |
| Begin period cash flow | 131.34M | 142.09M | 11.97M | 51.96M | - |
| End period cash flow | 128.00M | 131.34M | 142.09M | 11.97M | 51.96M |
| Total cash from operating activities | -120.14M | -132.76M | -89.08M | -39.36M | -0.56M |
| Issuance of capital stock | 107.37M | 9.01M | 131.87M | 127.18M | - |
| Depreciation | 3.68M | 0.97M | 0.62M | 0.32M | 0.32M |
| Other cashflows from investing activities | - | 91.00M | 26.76M | -127.50M | 108.00M |
| Dividends paid | - | 0.00M | - | - | 0.00M |
| Change to inventory | -3.45M | -0.49M | -0.49M | -0.49M | -0.49M |
| Change to account receivables | -20.73M | -20.73M | -20.73M | -20.73M | 0.00M |
| Sale purchase of stock | 15.59M | 9.01M | 131.87M | 127.18M | 59.79M |
| Other cashflows from financing activities | -13.87M | 64.45M | 49.42M | 59.98M | 49.42M |
| Change to netincome | 27.01M | 23.09M | 12.55M | 5.74M | 21.81M |
| Capital expenditures | 0.28M | 19.02M | 0.23M | 0.28M | 0.28M |
| Change receivables | -20.73M | - | - | - | 0.00M |
| Cash flows other operating | 3.52M | 121.53M | -2.42M | - | 0.00M |
| Exchange rate changes | - | - | - | - | 0.00M |
| Cash and cash equivalents changes | -3.35M | -10.74M | 130.09M | - | 0.00M |
| Change in working capital | -21.05M | 16.98M | 0.61M | 7.12M | - |
| Stock based compensation | 27.01M | 23.09M | 12.55M | 6.07M | - |
| Other non cash items | 12.47M | -90.41M | 0.34M | -0.33M | - |
| Free cash flow | -120.41M | -151.78M | -89.30M | -39.64M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals Inc |
0.05 0.06% |
85.05 | - | 104.17 | 6.20 | 4.64 | 6.31 | -8.62 |
| NVO Novo Nordisk A/S |
0.70 1.76% |
40.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.79 0.50% |
556.10 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
39.36 4.24% |
967.25 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher Peetz | Pres, CEO & Director | 1979 |
| Dr. Ian Clements | Chief Financial Officer | 1969 |
| Mr. Peter Radovich M.B.A., Ph.D. | Chief Operating Officer | 1978 |
| Mr. Paul K. Ross | Chief Compliance Officer | NA |
| Ms. Erin Campany | Sr. VP of HR | 1968 |
| Dr. Pamela Vig Ph.D. | Head of R&D | 1971 |
| Ms. Lara Longpre MBA, MSC | Chief Devel. Officer | 1970 |
| Ms. Vinita P. Kumar | Sr. vice Pres of Quality | NA |
| Mr. Christopher Peetz | CEO & Director | 1979 |
| Mr. Peter Radovich M.B.A., Ph.D. | COO & President | 1978 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.40%
Communication Services
+0.50%
Consumer Cyclical
+1.37%
Consumer Defensive
+0.86%
Energy
-2.31%
Financial Services
+0.99%
Financials
+0.52%
Healthcare
-0.64%
Industrials
+0.63%
Real Estate
+0.65%
Technology
-0.08%
Utilities
+0.01%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...